Compass Therapeutics (CMPX) Common Equity (2018 - 2026)
Compass Therapeutics (CMPX) posted Common Equity of $186.5 million for Q1 2026, down 5.24% sequentially from $196.8 million in Q4 2025, and up 69.09% YoY from $110.3 million in Q1 2025.
Compass Therapeutics (CMPX) Common Equity (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Common Equity for 9 years, with the latest figure at $186.5 million in Q1 2026.
- Quarterly Common Equity rose 69.09% year-over-year to $186.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.5 million (up 69.09% YoY) and the FY2025 annual result came in at $196.8 million, up 57.14% from the prior year.
- Common Equity declined to $186.5 million in Q1 2026 per CMPX's latest filing, from $196.8 million in the prior quarter.
- Over five years, Common Equity peaked at $209.6 million in Q3 2025 and troughed at $93.2 million in Q2 2025.
- A 5-year average of $151.4 million and a median of $148.5 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 386.09% in 2022, then sank 36.21% in 2025.
- Over 5 years, Common Equity stood at $181.6 million in 2022, then fell by 18.22% to $148.5 million in 2023, then decreased by 15.69% to $125.2 million in 2024, then jumped by 57.14% to $196.8 million in 2025, then decreased by 5.24% to $186.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $186.5 million, $196.8 million, and $209.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | 166.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 166.05 Mn |
| Mar 31, 2026 | 186.47 Mn |
| Dec 31, 2025 | 196.79 Mn |
| Sep 30, 2025 | 209.61 Mn |
| Jun 30, 2025 | 93.21 Mn |
| Mar 31, 2025 | 110.28 Mn |
| Dec 31, 2024 | 125.23 Mn |
| Sep 30, 2024 | 138.40 Mn |
| Jun 30, 2024 | 146.10 Mn |
| Mar 31, 2024 | 157.06 Mn |
| Dec 31, 2023 | 148.54 Mn |
| Sep 30, 2023 | 160.05 Mn |
| Jun 30, 2023 | 168.29 Mn |
| Mar 31, 2023 | 175.27 Mn |
| Dec 31, 2022 | 181.64 Mn |
| Sep 30, 2022 | 116.12 Mn |
| Jun 30, 2022 | 126.93 Mn |
| Mar 31, 2022 | 134.49 Mn |
| Dec 31, 2021 | 140.08 Mn |
| Sep 30, 2021 | 23.89 Mn |